These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 29396841

  • 1. Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy.
    Dimitriadis GK, Randeva HS, Aftab S, Ali A, Hattersley JG, Pandey S, Grammatopoulos DK, Valsamakis G, Mastorakos G, Jones TH, Barber TM.
    Endocrine; 2018 Apr; 60(1):175-184. PubMed ID: 29396841
    [Abstract] [Full Text] [Related]

  • 2. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
    Giagulli VA, Carbone MD, Ramunni MI, Licchelli B, De Pergola G, Sabbà C, Guastamacchia E, Triggiani V.
    Andrology; 2015 Nov; 3(6):1094-103. PubMed ID: 26447645
    [Abstract] [Full Text] [Related]

  • 3. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.
    Yassin DJ, Doros G, Hammerer PG, Yassin AA.
    J Sex Med; 2014 Jun; 11(6):1567-76. PubMed ID: 24712761
    [Abstract] [Full Text] [Related]

  • 4. Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study.
    Francomano D, Bruzziches R, Barbaro G, Lenzi A, Aversa A.
    J Endocrinol Invest; 2014 Apr; 37(4):401-11. PubMed ID: 24639122
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome.
    Aversa A, Bruzziches R, Francomano D, Spera G, Lenzi A.
    J Endocrinol Invest; 2010 Dec; 33(11):776-83. PubMed ID: 20220293
    [Abstract] [Full Text] [Related]

  • 6. Testosterone undecanoate improves sexual function in men with type 2 diabetes and severe hypogonadism: results from a 30-week randomized placebo-controlled study.
    Hackett G, Cole N, Saghir A, Jones P, Strange RC, Ramachandran S.
    BJU Int; 2016 Nov; 118(5):804-813. PubMed ID: 27124889
    [Abstract] [Full Text] [Related]

  • 7. Two-Year Analysis of a New Oral Testosterone Undecanoate (TU) Formulation in Hypogonadal Men: Efficacy, Impact on Psychosexual Function, and Safety.
    Honig S, Gittelman M, Kaminetsky J, Wang C, Amory JK, Rohowsky N, Dudley RE, Woun Seo B, Newmark J, Swerdloff R.
    J Sex Med; 2022 Dec; 19(12):1750-1758. PubMed ID: 36272969
    [Abstract] [Full Text] [Related]

  • 8. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study.
    Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P, BLAST Study Group.
    J Sex Med; 2014 Mar; 11(3):840-56. PubMed ID: 24308723
    [Abstract] [Full Text] [Related]

  • 9. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism.
    Schubert M, Minnemann T, Hübler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F.
    J Clin Endocrinol Metab; 2004 Nov; 89(11):5429-34. PubMed ID: 15531493
    [Abstract] [Full Text] [Related]

  • 10. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
    Permpongkosol S, Khupulsup K, Leelaphiwat S, Pavavattananusorn S, Thongpradit S, Petchthong T.
    J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
    [Abstract] [Full Text] [Related]

  • 11. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
    Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H, Maggi M.
    J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
    [Abstract] [Full Text] [Related]

  • 12. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency.
    Boyanov MA, Boneva Z, Christov VG.
    Aging Male; 2003 Mar; 6(1):1-7. PubMed ID: 12809074
    [Abstract] [Full Text] [Related]

  • 13. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism.
    Minnemann T, Schubert M, Freude S, Hübler D, Gouni-Berthold I, Schumann C, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F.
    J Endocrinol Invest; 2008 Aug; 31(8):718-23. PubMed ID: 18852533
    [Abstract] [Full Text] [Related]

  • 14. The HEAT-Registry (HEmatopoietic Affection by Testosterone): comparison of a transdermal gel vs long-acting intramuscular testosterone undecanoate in hypogonadal men.
    Zitzmann M, Cremers JF, Krallmann C, Kliesch S.
    Aging Male; 2022 Dec; 25(1):134-144. PubMed ID: 35467476
    [Abstract] [Full Text] [Related]

  • 15. A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal men.
    Zhang GY, Gu YQ, Wang XH, Cui YG, Bremner WJ.
    J Androl; 1998 Dec; 19(6):761-8. PubMed ID: 9876028
    [Abstract] [Full Text] [Related]

  • 16. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome.
    Francomano D, Ilacqua A, Bruzziches R, Lenzi A, Aversa A.
    Urology; 2014 Jan; 83(1):167-73. PubMed ID: 24139347
    [Abstract] [Full Text] [Related]

  • 17. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.
    Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, Wilkinson P.
    J Sex Med; 2013 Jun; 10(6):1612-27. PubMed ID: 23551886
    [Abstract] [Full Text] [Related]

  • 18. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study.
    Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A, Spera G.
    J Sex Med; 2010 Oct; 7(10):3495-503. PubMed ID: 20646185
    [Abstract] [Full Text] [Related]

  • 19. Serum testosterone and bioavailable testosterone correlate with age and body size in hypogonadal men treated with testosterone undecanoate (1000 mg IM--Nebido).
    Moisey R, Swinburne J, Orme S.
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):642-7. PubMed ID: 18394021
    [Abstract] [Full Text] [Related]

  • 20. A New Oral Testosterone Undecanoate Formulation Restores Testosterone to Normal Concentrations in Hypogonadal Men.
    Swerdloff RS, Wang C, White WB, Kaminetsky J, Gittelman MC, Longstreth JA, Dudley RE, Danoff TM.
    J Clin Endocrinol Metab; 2020 Aug 01; 105(8):2515-31. PubMed ID: 32382745
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.